Fate Therapeutics Inc

NASDAQ:FATE 4:00:00 PM EDT

4.79

-0.25 (-4.96%)

4:20:00 PM EDT: $4.79 0.00 (0.00%)

Market Cap (Intraday)	475.35M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1.66 Million
Adjusted EPS	-$0.48

See more estimates

10-Day MA	$5.64
50-Day MA	$6.87
200-Day MA	$4.09

See more pivots

Fate Therapeutics Inc Stock, NASDAQ:FATE

12278 Scripps Summit Drive, Suite 200, San Diego, California 92131

United States of America

Phone: +1.858.875.1800

Number of Employees: 181

http://www.fatetherapeutics.com

Description

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.